Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | TNO155 |
| Trade Name | |
| Synonyms | TNO-155|TNO 155 |
| Drug Descriptions |
TNO155 is an inhibitor of PTPN11 (SHP2), which potentially blocks SHP2 signaling, thereby inhibiting activation of the MAPK pathway and subsequent tumor cell growth (PMID: 38032104, Cancer Res (2022) 82 (12_Supplement): 1054). |
| DrugClasses | SHP2 Inhibitor 20 |
| CAS Registry Number | NA |
| NCIT ID | C139559 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Adagrasib + TNO155 | Adagrasib TNO155 | 0 | 1 |
| BI-3406 + TNO155 | BI-3406 TNO155 | 0 | 0 |
| Ceritinib + TNO155 | Ceritinib TNO155 | 2 | 0 |
| Crizotinib + TNO155 | Crizotinib TNO155 | 2 | 0 |
| Dabrafenib + LTT462 + TNO155 | Dabrafenib LTT462 TNO155 | 0 | 1 |
| Dabrafenib + TNO155 + Trametinib | Dabrafenib TNO155 Trametinib | 0 | 1 |
| Entrectinib + TNO155 | Entrectinib TNO155 | 0 | 0 |
| JDQ443 + Spartalizumab + TNO155 | JDQ443 Spartalizumab TNO155 | 0 | 0 |
| JDQ443 + Tislelizumab + TNO155 | JDQ443 TNO155 Tislelizumab | 0 | 1 |
| JDQ443 + TNO155 | JDQ443 TNO155 | 0 | 1 |
| Lorlatinib + TNO155 | Lorlatinib TNO155 | 2 | 0 |
| MRTX-1133 + TNO155 | MRTX-1133 TNO155 | 0 | 0 |
| MRTX1257 + TNO155 | MRTX1257 TNO155 | 0 | 0 |
| Osimertinib + TNO155 | Osimertinib TNO155 | 0 | 0 |
| Poziotinib + TNO155 | Poziotinib TNO155 | 0 | 0 |
| Ribociclib + TNO155 | Ribociclib TNO155 | 0 | 1 |
| Sotorasib + TNO155 | Sotorasib TNO155 | 0 | 1 |
| Spartalizumab + TNO155 | Spartalizumab TNO155 | 0 | 1 |
| TNO155 | TNO155 | 4 | 1 |